Acumen Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Acumen Pharmaceuticals has a total shareholder equity of $243.9M and total debt of $29.4M, which brings its debt-to-equity ratio to 12%. Its total assets and total liabilities are $288.9M and $45.0M respectively.
Key information
12.0%
Debt to equity ratio
US$29.38m
Debt
Interest coverage ratio | n/a |
Cash | US$260.47m |
Equity | US$243.95m |
Total liabilities | US$44.97m |
Total assets | US$288.91m |
Recent financial health updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Financial Position Analysis
Short Term Liabilities: ABOS's short term assets ($266.9M) exceed its short term liabilities ($15.4M).
Long Term Liabilities: ABOS's short term assets ($266.9M) exceed its long term liabilities ($29.6M).
Debt to Equity History and Analysis
Debt Level: ABOS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABOS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABOS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ABOS has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 43.4% each year.